We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Eli Lilly’s stock price fell to $872.91. Shareholders have lost 8.3% of their capital, which is disappointing considering the ...

Dr. Mehmet Oz, nominated to run the Centers for Medicare & Medicaid Services, will sell shares in Eli Lilly and UnitedHealth.

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

This is a great tragedy; many investors will be morally inclined to support Eli Lilly as well as financially. I expect that this moral stance will only help to sustain sentiment for the stock as ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts ...

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share ...

Eli Lilly exceeded analyst forecasts for both sales and earnings in Q4 2024. As has been true for a while, sales of GLP-1 drugs Mounjaro and Zepbound drove both sales and earnings growth.

Eli Lilly, the world’s biggest drugmaker ... Mounjaro's revenue rose to $3.53 billion. Lilly's stock climbed more than 2% Thursday morning.

Eli Lilly LLY confirmed its fourth ... which supports Lilly’s wide moat, but we think the market assigns the stock too high a premium, considering long-term headwinds from obesity competition.

The stock is up 19.23% over the past year, 8.22% YTD. Let’s look at what the charts indicate for Eli Lilly stock and how the stock currently maps against Wall Street estimates. LLY stock is ...